Ipamorelin (5mg) protocols focus on this selective growth hormone secretagogue peptide that stimulates natural growth hormone release from the pituitary gland. Unlike older GH-releasing peptides, Ipamorelin is known for its targeted action on ghrelin receptors with minimal impact on cortisol or prolactin levels. It is commonly used in research settings for recovery, body composition support, and anti-aging-related pathways. This guide outlines a subcutaneous administration approach optimized for the 5 mg vial format.
Concise summary of the subcutaneous regimen.
Suggested approach for the 5 mg vial format.
Ipamorelin is a selective growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a) in the pituitary gland and hypothalamus. This stimulates the natural pulsatile release of growth hormone without directly increasing cortisol or prolactin in typical research observations.
The increased growth hormone signaling may indirectly support insulin-like growth factor-1 (IGF-1) production in the liver, which plays a key role in tissue repair, muscle growth, fat metabolism, and recovery. Its selectivity makes it one of the more targeted GH-releasing peptides studied in preclinical and early research contexts.
Observations based on preclinical and early-stage research.
Potential Benefits:
Possible Side Effects: